ZYBERNO
Stock Report
Updated Aug 21, 2026

Lucid Diagnostics Inc. (LUCD)

Healthcare • NASDAQ

$0.96

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
18.0/100
POOR BUSINESS
Lucid Diagnostics Inc. (LUCD) scores 18/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-404.3%)
Debt-to-Equity (Solvency Risk):CRITICAL (2.14x)
Operating Margin (Operational Efficiency):CRITICAL (-930.8%)
Return on Capital (Capital Efficiency):CRITICAL (-685.9%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Lucid Diagnostics Inc. (LUCD) stock report — Zyberno Score 18/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.96
Market Cap:$176.35M

Valuation Multiples (3)

P/B Ratio:16.14x
P/S Ratio:32.39x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$144.35M

Price Action & Momentum (3)

Momentum Percentile:31 / 100
% of 52-Week High:59.1%
B. Profitability Assessment

Return Metrics (5)

ROA:-125.4%
Reinvestment Rate:1.8%
Fundamental Growth Rate (g):-12.2%

Margin Analysis (3)

Operating Margin Ttm:-930.8%
Net Margin Ttm:-959.8%
Ebitda Margin:-909.0%

TTM Performance (2)

Operating Margin Ttm:-930.8%
Net Margin Ttm:-959.8%

Yield Metrics (2)

Earnings Yield:-$90.16
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):77.4%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.33x
Quick Ratio:1.31x
Cash Ratio:1.21x

Leverage Analysis (3)

Debt To Equity Ttm:2.14x
Debt-to-Equity Ratio:2.14x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-2,920.00x
Times Interest Earned:-2,920.00

Capital Structure (4)

Working Capital:9,107,000.00
Cash And Cash Equivalents:33,404,000.00
Long Term Debt:$503.00K
Net Debt:-$32.00M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $5.45M
Linear Growth: 77.4%
📊 Click to view full LUCD Revenue analysis & methodology →
Cost Of Revenue Ttm:$6.67M

Profitability Breakdown (2)

-$1.96M-$50.68M

Bottom Line Performance (3)

-$52.26M
Income Before Tax:-$52.26M
Ebitda Ttm:-49,497,000.00

Operating Expenses (5)

Operating Expenses:56,129,000.00
R And D Expense:5,393,000.00
Sga Expense:23,277,000.00
Income Tax Expense:$0.00
Interest Expense:17,000.00

Expense Ratios (3)

R And D To Revenue Percentage:365.9%
Sga To Revenue Percentage:1,579.2%
Ebitda Margin:-909.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$38.95M
Current Assets:$36.62M
Ppe Net:810,000.00
Goodwill:0.00
Intangible Assets:$105.00K

Liability Structure (4)

Total Liabilities:28,019,000.00
Current Liabilities:27,516,000.00
Long Term Debt:$503.00K
Short Term Debt:$906.00K

Equity & Capital (3)

Equity:$10.93M
Retained Earnings:-$312.68M
Common Stock:400,000,000.00

Working Capital Items (3)

Accounts Receivable:1,088,000.00
Inventory:484,000.00
Accounts Payable:2,443,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:1,694,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$46.12M-$46.68M

Investment Activities (1)

Investing Cash Flow:-$215.00K

Financing Activities (3)

Financing Cash Flow:$5.49M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$2.65M

Non-Cash Items (1)

Depreciation Amortization Ttm:1,187,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.94
-$0.87
Earnings Per Share Ttm:-$0.29

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.03
Operating Cash Flow Per Share:-$0.25

Book Value & Capital (2)

Book Value Per Share:$0.06
Cash Per Share:0.18

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.13x
Working Capital Turnover Ttm:0.60x

Receivables Management (2)

Receivables Turnover Ttm:5.00x
Days Sales Outstanding Ttm:72.93

Inventory Management (2)

Inventory Turnover Ttm:13.78x
Days Inventory Outstanding Ttm:26.49

Payables & Cash Cycle (2)

Days Payable Outstanding:133.69
Cash Conversion Cycle:-34.27
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:80.00
Quality Score:35.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:1.8%
Fundamental Growth Rate (g):-12.2%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):77.4%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-27.8%
C. Company Profile & Context

Corporate Information (6)

Symbol:LUCD
Company Name:Lucid Diagnostics Inc.
Sector:Healthcare
Industry:Medical Devices
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:183.12M
Shares Outstanding Basic:183.12M
Shares Outstanding Diluted:108.18M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-21 17:22:45 UTC
Data Timestamp:2026-08-18T23:41:47.256472
Scroll to Top